Home > Boards > US Listed > Biotechs > Opko Health Inc (OPK)

MIAMI, Oct. 13, 2020 (GLOBE NEWSWIRE) -- OPKO

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
JDUB Member Profile
 
Followed By 43
Posts 8,721
Boards Moderated 1
Alias Born 12/07/03
160x600 placeholder
Sian Capital Sends Letter to OPKO Health Regarding its Decision to Apparently Withhold Rayaldee From Many Patients Amidst COV... GlobeNewswire Inc. - 11/20/2020 4:45:00 PM
Sian Capital Issues Open Letter to Stockholders of OPKO Health GlobeNewswire Inc. - 11/12/2020 6:30:00 PM
OPKO Health to Participate in Three Upcoming Investment Conferences GlobeNewswire Inc. - 11/11/2020 9:10:51 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/2/2020 6:57:26 AM
Sian Capital Highlights Paths to Meaningful Value Creation at OPKO Health GlobeNewswire Inc. - 10/29/2020 5:20:36 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 10/29/2020 4:26:16 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/29/2020 4:08:24 PM
OPKO Health Reports 2020 Third Quarter Business Highlights and Financial Results GlobeNewswire Inc. - 10/29/2020 4:05:10 PM
OPKO Health's BioReference Laboratories Launches Multiplex COVID-19 and Influenza A/B Test PR Newswire (US) - 10/20/2020 8:00:00 AM
OPKO Health to Report Third Quarter 2020 Financial Results on October 29, 2020 GlobeNewswire Inc. - 10/13/2020 12:50:49 PM
OPKO Health's BioReference Laboratories Launches COVID-19 Testing Program for New York City Schools PR Newswire (US) - 10/9/2020 8:00:00 AM
Notice of Class Action Settlement Involving Purchasers of OPKO Health, Inc. Common Stock during the period of September 26, 2... PR Newswire (US) - 10/8/2020 9:08:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/15/2020 10:32:13 AM
OPKO Health Initiates Clinical Trial of RAYALDEE in COVID-19 Patients GlobeNewswire Inc. - 9/15/2020 7:00:10 AM
TNS New Potential Home Run Report Available Now InvestorsHub NewsWire - 9/3/2020 8:35:00 AM
OPKO Health to Participate in Two September Investment Conferences GlobeNewswire Inc. - 9/2/2020 4:05:10 PM
OPKO Health's BioReference Laboratories Announces New York City Schools COVID-19 Testing Program PR Newswire (US) - 9/2/2020 8:00:00 AM
OPKO Health's BioReference Laboratories Launches Best-in-Class Next-Generation Sequencing (NGS) Assay PR Newswire (US) - 9/1/2020 3:55:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/27/2020 8:41:29 AM
OPKO Health's GeneDx Enters into Agreement with Pediatrix Medical Group to Offer Neonatal Genomic Services PR Newswire (US) - 8/12/2020 9:15:00 AM
OPKO Health's GeneDx Adds GenomeXpress to Its Industry-Leading Clinical Genomics Portfolio PR Newswire (US) - 8/6/2020 8:00:00 AM
OPKO Health to Participate in BTIG Virtual Biotechnology Conference GlobeNewswire Inc. - 8/5/2020 3:35:52 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 7/31/2020 8:54:32 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/31/2020 6:28:10 AM
OPKO Health Reports 2020 Second Quarter Business Highlights and Financial Results GlobeNewswire Inc. - 7/30/2020 4:05:10 PM
JDUB   Tuesday, 10/13/20 12:52:15 PM
Re: JDUB post# 13190
Post # of 13870 
MIAMI, Oct. 13, 2020 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended September 30, 2020, as well as discuss financial guidance, after the close of the U.S. financial markets on Thursday, October 29, 2020. OPKO’s senior management will provide a business update and discuss results in greater detail during a conference call and live audio webcast on October 29th beginning at 4:30 p.m. Eastern time.

CONFERENCE CALL & WEBCAST INFORMATION

OPKO encourages participants to pre-register for the conference call using the link here or dialing (888) 869-1189 or (706) 643-5902 and using conference ID 4542807. Upon registering, participants will receive dial-in numbers, an event passcode and a unique registrant ID to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the start of the call.

To access the live call via webcast, please click on the link OPKO 3Q20 Results Conference Call. Individual investors and investment community professionals who do not plan to ask a question during the call’s Q&A session are encouraged to listen to the call via the webcast.

For those unable to listen to the live conference call, a replay can be accessed for a period of time on OPKO’s website at OPKO 3Q20 Results Conference Call. A telephone replay will be available beginning approximately two hours after the close of the conference call. To access the replay, please dial (855) 859-2056 or (404) 537-3406, and use conference ID 4542807.

About OPKO Health

OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. For more information, visit www.opko.com.

Contacts:

LHA Investor Relations
Yvonne Briggs, 310-691-7100
ybriggs@lhai.com
or
Bruce Voss, 310-691-7100
bvoss@lhai.com



Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences